Executive Summary
Generated July 30, 2026
Neurotechnology
Paradromics
Strategic importance is our editorial rating of how central this entity is to the technology landscape we track; confidence reflects how well-sourced and current the underlying evidence is.
1
Chokepoint Score
1 other entity structurally depend on this one
Headquarters
Austin, Texas, USA
Website
Employees
90 (2026, approximate)
Founded
2015
Listing
private
Overview
Developer of the Connexus brain-computer interface, a wireless implant designed to record and decode brain signals at the individual-neuron level to restore communication for patients with severe speech impairment. Neurosurgeons at University of Michigan Health completed the first-in-human implantation of the wireless Connexus BCI in 2026 as part of the multi-site Connect-One clinical study, following FDA approval of the study and Paradromics' acceptance into an FDA regulatory accelerator program with a new patient registry.
Strategic Connections
- Brain-Computer Interfaces: Paradromics develops the Connexus brain-computer interface, a wireless implant recording brain activity at individual-neuron resolution to restore communication.
- Neuralink: Paradromics competes with Neuralink in the race toward high-bandwidth implantable brain-computer interfaces for speech and motor restoration.
- Precision Neuroscience: Paradromics competes with Precision Neuroscience, both pursuing speech-restoration applications via distinct BCI architectures.
Strategic Risks
- Surgical implant procedures carry inherent safety and regulatory risk
- Small initial trial population and six-year follow-up requirement lengthen the path to broad commercial approval
Future Outlook
- Expanding the multi-site Connect-One clinical study beyond its initial University of Michigan site
- FDA regulatory accelerator program participation could shorten the path to eventual approval
Sources
2 sources, 69% average source confidence — full citations in the Full Analyst Report.
Generated by InsightNodes — Technology Intelligence Platform. This report reflects sourced, evidence-backed information as of the dates cited above and is not investment advice.
Viewing the Executive Summary — switch to the Full Analyst Report.